These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24934297)

  • 21. Semisolid SLN dispersions for topical application: influence of formulation and production parameters on viscoelastic properties.
    Lippacher A; Müller RH; Mäder K
    Eur J Pharm Biopharm; 2002 Mar; 53(2):155-60. PubMed ID: 11879997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Qualitative High-Throughput Analysis of Subvisible Particles in Biological Formulations Using Backgrounded Membrane Imaging.
    Murphy MI; Bruque M; Hanford A; Trayton I; Handali M; Leissa JA; Hasige S; Day K; Patel SM
    J Pharm Sci; 2022 Jun; 111(6):1605-1613. PubMed ID: 35318031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of a Best Practice Approach Using Resonant Mass Measurement for Biotherapeutic Product Characterization.
    Krueger AB; Hadley J; Cheney PP; Markova N; Carpenter JF; Fradkin AH
    J Pharm Sci; 2019 May; 108(5):1675-1685. PubMed ID: 30599170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the Role of the Air-Solution Interface on the Mechanism of Subvisible Particle Formation Caused by Mechanical Agitation for an IgG1 mAb.
    Ghazvini S; Kalonia C; Volkin DB; Dhar P
    J Pharm Sci; 2016 May; 105(5):1643-1656. PubMed ID: 27025981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A critical review of analytical methods for subvisible and visible particles.
    Narhi LO; Jiang Y; Cao S; Benedek K; Shnek D
    Curr Pharm Biotechnol; 2009 Jun; 10(4):373-81. PubMed ID: 19519412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags.
    Kumru OS; Liu J; Ji JA; Cheng W; Wang YJ; Wang T; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2012 Oct; 101(10):3636-50. PubMed ID: 22733600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.
    Hubert M; Yang DT; Kwok SC; Rios A; Das TK; Patel A; Wuchner K; Antochshuk V; Junge F; Bou-Assaf GM; Cao S; Saggu M; Montrond L; Afonina N; Kolhe P; Loladze V; Narhi L
    J Pharm Sci; 2020 Jan; 109(1):830-844. PubMed ID: 31647951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitation of protein particles in parenteral solutions using micro-flow imaging.
    Huang CT; Sharma D; Oma P; Krishnamurthy R
    J Pharm Sci; 2009 Sep; 98(9):3058-71. PubMed ID: 18937372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of shear and extensional viscosity on atomization in medical inhaler.
    Broniarz-Press L; Ochowiak M; Matuszak M; Włodarczak S
    Int J Pharm; 2014 Jul; 468(1-2):199-206. PubMed ID: 24746416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers.
    Buttini F; Miozzi M; Balducci AG; Royall PG; Brambilla G; Colombo P; Bettini R; Forbes B
    Int J Pharm; 2014 Apr; 465(1-2):42-51. PubMed ID: 24491530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
    Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
    Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introducing the Alba
    Chillon A; Pace A; Zuccato D
    PDA J Pharm Sci Technol; 2018; 72(4):382-392. PubMed ID: 29853611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of Subvisible Particles in Biotherapeutic Prefilled Syringes: The Role of Polysorbate and Protein on the Formation of Silicone Oil and Protein Subvisible Particles After Drop Shock.
    Jiao N; Barnett GV; Christian TR; Narhi LO; Joh NH; Joubert MK; Cao S
    J Pharm Sci; 2020 Jan; 109(1):640-645. PubMed ID: 31689431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles--Differential Centrifugation and FACS.
    Boll B; Folzer E; Finkler C; Huwyler J; Mahler HC; Schmidt R; Koulov AV
    Pharm Res; 2015 Dec; 32(12):3952-64. PubMed ID: 26195006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Issues and challenges of subvisible and submicron particulate analysis in protein solutions.
    Scherer TM; Leung S; Owyang L; Shire SJ
    AAPS J; 2012 Jun; 14(2):236-43. PubMed ID: 22391789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Comprehensive Evaluation of Nanoparticle Tracking Analysis (NanoSight) for Characterization of Proteinaceous Submicron Particles.
    Tian X; Nejadnik MR; Baunsgaard D; Henriksen A; Rischel C; Jiskoot W
    J Pharm Sci; 2016 Nov; 105(11):3366-3375. PubMed ID: 27663383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a lyophilized plasmid/LPEI polyplex formulation with long-term stability--A step closer from promising technology to application.
    Kasper JC; Schaffert D; Ogris M; Wagner E; Friess W
    J Control Release; 2011 May; 151(3):246-55. PubMed ID: 21223985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcium Chloride and Calcium Gluconate in Neonatal Parenteral Nutrition Solutions with Added Cysteine: Compatibility Studies Using Laser Light Obscuration Methodology.
    Huston RK; Christensen JM; Alshahrani SM; Mohamed SM; Heisel CF; Stout KN
    JPEN J Parenter Enteral Nutr; 2019 Mar; 43(3):426-433. PubMed ID: 30156306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Critical evaluation and guidance for using the Coulter method for counting subvisible particles in protein solutions.
    Barnard JG; Rhyner MN; Carpenter JF
    J Pharm Sci; 2012 Jan; 101(1):140-53. PubMed ID: 22109687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of a mixture DOE for the prediction of formulation critical temperatures during lyophilisation process optimisation.
    Gervasi V; Cullen S; McCoy T; Crean A; Vucen S
    Int J Pharm; 2019 Dec; 572():118807. PubMed ID: 31678526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.